SABASTINE AGHAZIEM: Open Payments
NPI 1477189371 · YUBA CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$613 in 23 payments from 9 companies in 2025. Trend: 2023 $930 · 2024 $700 · 2025 $613
Food & beverage: $613
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 8 | $209 |
| ABBVIE INC. | 6 | $147 |
| Ipsen Biopharmaceuticals, Inc | 2 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $55 |
| Gilead Sciences, Inc. | 2 | $37 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $31 |
| Janssen Biotech, Inc. | 1 | $29 |
| Novo Nordisk Inc | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: VELSIPITY, MAVYRET, IQIRVO, XIFAXAN, JOURNAVX, LINZESS, TREMFYA, EOHILIA.
Industry payments across CA — which companies pay providers there.
